Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025
Archives of Iranian Medicine · 2024
DOI: 10.34172/aim.2024.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Iranian Medicine, 2024. Verfasst von Hani AziziKia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Registries. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
While there has been extensive research on colorectal cancer (CRC) incidence and its associated factors in Iran, a significant gap exists in studies predicting its future trends. Our study aimed to thoroughly report CRC incidence across Iran from 2014 to 2017, by sex, age, and geographical regions, and provide a projection for 2025.
Methods
This retrospective study utilized data from the Iranian National Population-based Cancer Registry (INPCR). Patients with the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes C18 to C21 were included. The age-standardized incidence rate (ASR), was calculated per 100000 individuals annually, and crude incidence rates were retrieved for various demographic groups and years.
Results
Between 2014 and 2017, a total of 43580 new CRC cases (55.96% males) were registered. Men exhibited an ASR of 134.45, while women’s ASR was 94.85. The highest ASRs were observed in Tehran, Qom, and Ilam (18.99, 18.26, and 18.06, respectively). Incidence rates surpassed 20 after age 50 for both genders, reaching their peak within the 80–84 age group. Adenocarcinoma was the most frequent histological type of CRC in nearly all provinces. Case numbers and ASRs are projected to continuously rise until 2025, with a predominance of male cases.
Conclusion
The anticipated increase in CRC incidence in Iran emphasizes the need for additional studies to better identify risk factors. Furthermore, implementing screening programs is recommended for individuals at a higher risk of CRC, including men, the elderly population, and those residing in regions with a notable prevalence of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
- Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran.
- Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Hani AziziKia
Zitieren
APA
AziziKia, H., Teymourzadeh, A., Kouchaki, H., Nakhostin-Ansari, A., Jafari Doudaran, P., Ahmadinejad, I., Hoveidaei, A., & Roshandel, G. (2024). Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025. Archives of Iranian Medicine. https://doi.org/10.34172/aim.2024.26
Vancouver
AziziKia H, Teymourzadeh A, Kouchaki H, Nakhostin-Ansari A, Jafari Doudaran P, Ahmadinejad I, et al. Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025. Archives of Iranian Medicine. 2024. doi:10.34172/aim.2024.26
BibTeX
@article{AziziKia2024,
author = {AziziKia, Hani and Teymourzadeh, Azin and Kouchaki, Hosein and Nakhostin-Ansari, Amin and Jafari Doudaran, Pooya and Ahmadinejad, Izadmehr and Hoveidaei, Armin and Roshandel, Gholamreza},
title = {Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014–2017 and Projected Rates to 2025},
journal = {Archives of Iranian Medicine},
year = {2024},
doi = {10.34172/aim.2024.26}
}
EUVIMED